Search research articles
Contact Us
Filters
Showing results (161-170 of 173) with videos related to
Page
of 18
Sort By:
The Lancet. Oncology
|
December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
NPJ Precision Oncology
|
July 11, 2026
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program
Heura Domènech, Sara Simonetti, Paula Romero-Lozano, et al.
Lancet (London, England)
|
September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman, Amit M Oza, Domenica Lorusso, et al.
The New England Journal of Medicine
|
February 9, 2022
Survival with Cemiplimab in Recurrent Cervical Cancer
Krishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.
Med (New York, N.Y.)
|
August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Nature Communications
|
May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Lancet (London, England)
|
April 13, 2026
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
Domenica Lorusso, Laurence Gladieff, David M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
Bradley J Monk, Christine Parkinson, Myong Cheol Lim, et al.
Cancer Research
|
April 15, 2022
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
Antonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 173) with videos related to
Sort By:
Page
of 18
The Lancet. Oncology
|
December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
NPJ Precision Oncology
|
July 11, 2026
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program
Heura Domènech, Sara Simonetti, Paula Romero-Lozano, et al.
Lancet (London, England)
|
September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman, Amit M Oza, Domenica Lorusso, et al.
The New England Journal of Medicine
|
February 9, 2022
Survival with Cemiplimab in Recurrent Cervical Cancer
Krishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.
Med (New York, N.Y.)
|
August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Nature Communications
|
May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Lancet (London, England)
|
April 13, 2026
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
Domenica Lorusso, Laurence Gladieff, David M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
Bradley J Monk, Christine Parkinson, Myong Cheol Lim, et al.
Cancer Research
|
April 15, 2022
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
Antonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
Page
of 18